Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.

Dorward, Jienchi.Lessells, Richard John.Drain, Paul K.Naidoo, Kogieleum.De Oliveira, Tulio De Paiva Nazareth Andrade.Pillay, Yogan.Abdool Karim, Salim Safurdeen.Garrett, Nigel Joel.2019-12-152019-12-1520182018Dorward, J., Lessells, R., Drain, P.K., Naidoo, K., de Oliveira, T., Pillay, Y., Abdool Karim, S.S. and Garrett, N. 2018. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV 5(7), e400-e404.http://dx.doi.org/10.1016/S2352-3018(18)30093-6https://researchspace.ukzn.ac.za/handle/10413/16649CAPRISA, 2018.Abstract available in pdf.enHIV.Antiretroviral therapy.Dolutegravir.Viral load.Adherence.Resistance.Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.Article